Literature DB >> 25896318

Design strategy for a smoking cessation trial of survival.

Jonathan J Shuster1.   

Abstract

Despite unequivocal evidence that smoking cessation is beneficial in terms of survival, there is at present no firm evidence that smoking cessation programs save lives. While they do increase quit rates, the collective evidence from randomized trials is inconclusive with respect to long-term survival. Withdrawal symptoms and the potential for harm when a subjects relapses after a prolonged period of cessation (e.g., 5+ years) might mitigate some or all of the benefits of the sustained quitters. This paper will review the key survival epidemiology and argue for a large randomized field trial of about 30,000 subjects, followed personally for 5 years and collectively for 15 years through the National Death Index. The intervention should be personalized, but reproducible through a treatment assignment algorithm. Personal coaching should be a major part of the intervention. Important short-term data on healthcare utilization should also be collected. Strong financial motivation for quitting (or prevention of smoking in the first place) is also presented. This paper is intended to motivate a large collective effort amongst the US Clinical and Translational Science Awardees to design the intervention and bring together the interested players to conduct the study.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  nicotine; personal coach; smoking; smoking relapse

Mesh:

Substances:

Year:  2013        PMID: 25896318      PMCID: PMC5350980          DOI: 10.1111/cts.12124

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  14 in total

1.  Should there be a moratorium on the use of cholesterol lowering drugs?

Authors:  G Davey Smith; J Pekkanen
Journal:  BMJ       Date:  1992-02-15

2.  A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation.

Authors:  Hillel R Alpert; Gregory N Connolly; Lois Biener
Journal:  Tob Control       Date:  2012-01-10       Impact factor: 7.552

3.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.

Authors:  Nicholas R Anthonisen; Melissa A Skeans; Robert A Wise; Jure Manfreda; Richard E Kanner; John E Connett
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

Review 4.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

5.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

6.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

7.  Placebo-controlled trial of cytisine for smoking cessation.

Authors:  Robert West; Witold Zatonski; Magdalena Cedzynska; Dorota Lewandowska; Joanna Pazik; Paul Aveyard; John Stapleton
Journal:  N Engl J Med       Date:  2011-09-29       Impact factor: 91.245

8.  Smoking cessation in relation to total mortality rates in women. A prospective cohort study.

Authors:  I Kawachi; G A Colditz; M J Stampfer; W C Willett; J E Manson; B Rosner; D J Hunter; C H Hennekens; F E Speizer
Journal:  Ann Intern Med       Date:  1993-11-15       Impact factor: 25.391

9.  Early and late weight gain following smoking cessation in the Lung Health Study.

Authors:  P O'Hara; J E Connett; W W Lee; M Nides; R Murray; R Wise
Journal:  Am J Epidemiol       Date:  1998-11-01       Impact factor: 4.897

10.  Hospitalizations and mortality in the Lung Health Study.

Authors:  Nicholas R Anthonisen; John E Connett; Paul L Enright; Jure Manfreda
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.